Vericel Corp Current Deferred Revenue Over Time
| VCEL Stock | USD 41.66 0.99 2.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vericel Corp Performance and Vericel Corp Correlation. Vericel |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.045 | Earnings Share 0.01 | Revenue Per Share 4.464 | Quarterly Revenue Growth 0.147 | Return On Assets (0.01) |
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Vericel Corp Ord and related stocks such as Collplant Biotechnologies, Keros Therapeutics, and Merus BV Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLGN | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 942 K | 207 K | 32 K | 32 K | 28.8 K | 27.4 K |
| KROS | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 1.9 M | 4.4 M | 7.1 M | 17.3 M | 19.8 M | 20.8 M |
| MRUS | 141.1 K | 141.1 K | 141.1 K | 2.2 M | 1.6 M | 1.7 M | 1.7 M | 8.7 M | 19.4 M | 18.8 M | 20.2 M | 34.7 M | 29.4 M | 22.7 M | 14.8 M |
| IPSC | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 5.3 M | 7.2 M | 4.4 M | 5.7 M |
| CMRX | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | (656 K) | (656 K) | (656 K) | (656 K) | (656 K) | (112 K) | (773 K) | (773 K) | (695.7 K) | (660.9 K) |
| DAWN | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 6.6 M | 25.5 M | 29.3 M | 30.8 M |
| XFOR | 430 K | 430 K | 430 K | 430 K | 430 K | 430 K | 504 K | 2.6 M | 737 K | 737 K | 737 K | 737 K | 737 K | 847.5 K | 1.2 M |
| MREO | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (163.7 K) | (177.7 K) | 5.4 M | 8.4 M | 8.4 M | 6.5 M | 7.4 M | 4.4 M |
| TERN | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 836 K | 1.2 M | 1.2 M | 1.4 M | 1.1 M |
| IDYA | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 27.6 M | 29 M | 8.6 M | 9.9 M | 19.3 M |
| SNDX | 2.4 M | 2.4 M | 2.4 M | 3.4 M | 3.4 M | 1.2 M | 1.2 M | 1.6 M | 1.5 M | 1.5 M | 1.5 M | 12.8 M | 39 M | 44.8 M | 47.1 M |
| XNCR | 5.1 M | 5.1 M | 1.9 M | 3.4 M | 2.3 M | 33.3 M | 95.5 M | 88.8 M | 40.1 M | 45.2 M | 92.6 M | 37.3 M | 30.3 M | 31.7 M | 42.9 M |
| RGNX | (655 K) | (655 K) | (655 K) | (655 K) | 153 K | 127 K | 600 K | 600 K | 600 K | 3.3 M | 449 K | 3.3 M | 1.8 M | 148 K | 140.6 K |
| CRNX | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (835 K) | (939 K) | 2.2 M | 2.1 M | 2.2 M |
| STOK | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | 12.7 M | 14.9 M | 15.3 M | 11.5 M |
| DYN | 45 M | 5 M | 95 M | 100 M | 20 M | 29 M | 5 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 6.3 M | 6 M |
| CYTK | 3.1 M | 76 K | 76 K | 14.7 M | 17 M | 20.9 M | 8.1 M | 9.6 M | 15.8 M | 12.1 M | 19.3 M | 34.4 M | 34.4 M | 39.5 M | 41.5 M |
| RVMD | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 17.1 M | 20.6 M | 18.9 M | 4.5 M | 4 M | 3.8 M |
| BPMC | 1 M | 1 M | 1 M | 1 M | 3.9 M | 5.9 M | 11.4 M | 5.4 M | 3.6 M | 6.2 M | 12.6 M | 36.6 M | 448.6 M | 812 K | 771.4 K |
| RLAY | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 3.4 M | 5.6 M | 248 K | 14.9 M | 17.1 M | 18 M |
Vericel Corp Ord and related stocks such as Collplant Biotechnologies, Keros Therapeutics, and Merus BV Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Vericel Corp Ord | VCEL |
| Classification | Pharmaceutical Products |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 41.66
Check out Vericel Corp Performance and Vericel Corp Correlation. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Vericel Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.